Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Net Margin (2022 - 2026)

Axsome Therapeutics' Net Margin history spans 5 years, with the latest figure at 33.76% for Q1 2026.

  • On a quarterly basis, Net Margin rose 1516.0% to 33.76% in Q1 2026 year-over-year; TTM through Mar 2026 was 26.59%, a 6207.0% increase, with the full-year FY2025 number at 28.69%, up 4577.0% from a year prior.
  • Net Margin hit 33.76% in Q1 2026 for Axsome Therapeutics, down from 14.59% in the prior quarter.
  • Over the last five years, Net Margin for AXSM hit a ceiling of 11.88% in Q1 2023 and a floor of 14982.4% in Q4 2024.
  • Historically, Net Margin has averaged 1048.22% across 5 years, with a median of 91.09% in 2024.
  • Biggest five-year swings in Net Margin: crashed -1484448bps in 2024 and later skyrocketed 1496781bps in 2025.
  • Tracing AXSM's Net Margin over 5 years: stood at 251.29% in 2022, then soared by 45bps to 137.92% in 2023, then crashed by -10763bps to 14982.4% in 2024, then skyrocketed by 100bps to 14.59% in 2025, then plummeted by -131bps to 33.76% in 2026.
  • Business Quant data shows Net Margin for AXSM at 33.76% in Q1 2026, 14.59% in Q4 2025, and 27.62% in Q3 2025.